U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07431489) titled 'Retinal Structural and Functional Changes in Patients Treated With BRAF/MEK Inhibitors' on Feb. 10.
Brief Summary: Patients treated with BRAF/MEK inhibitor combinations for malignant melanoma may develop retinal changes known as MEK inhibitor-associated retinopathy (MEKAR). These changes can affect the structure and function of the retina and may cause visual symptoms.
This prospective interventional study evaluates structural and functional retinal alterations in patients receiving BRAF/MEK inhibitor therapy. The study aims to determine how often MEKAR occurs, describe its clinical characteristics and course, compare its incidence...